Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 34,019 | 39,499 | 41,961 | 42,925 | 46,529 |
| Receivables | 32,170 | 29,765 | 26,620 | 39,290 | 22,592 |
| Inventories | 20,493 | 23,872 | 25,532 | 15,691 | 18,442 |
| TOTAL | $100,120 | $112,097 | $112,944 | $118,149 | $109,602 |
| Non-Current Assets | |||||
| PPE Net | 2,533 | 2,895 | 3,265 | 3,629 | 4,023 |
| Intangibles | 68,055 | 77,065 | 86,076 | 95,086 | 104,097 |
| Other Non-Current Assets | 36,434 | 28,139 | 23,192 | 24,839 | 17,276 |
| TOTAL | $107,022 | $108,099 | $112,533 | $123,554 | $125,396 |
| Total Assets | $207,142 | $220,196 | $225,477 | $241,703 | $234,998 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 0 | 0 | 0 | 17,500 | 8,000 |
| Accounts payable and accrued liabilities | 13,494 | 10,107 | 11,882 | 14,635 | 9,038 |
| Accrued Expenses | 52,215 | 53,897 | 53,910 | 67,735 | 62,664 |
| TOTAL | $65,709 | $107,300 | $66,487 | $99,870 | $79,702 |
| Non-Current Liabilities | |||||
| Long Term Debt | 38,355 | 38,031 | 30,145 | 17,183 | 34,613 |
| Deferred Revenues | N/A | 43,296 | 695 | N/A | 0 |
| Other Non-Current Liabilities | 153,480 | 102,320 | 112,807 | 111,938 | 116,809 |
| TOTAL | $191,835 | $146,650 | $186,248 | $172,417 | $194,718 |
| Total Liabilities | $257,544 | $253,950 | $252,735 | $272,287 | $274,420 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 218,181 | 210,288 | 209,596 | 209,372 | 188,389 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -1,655,556 | -1,635,517 | -1,626,935 | -1,608,950 | -1,609,564 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $-50,402 | $-33,754 | $-27,258 | $-30,584 | $-39,422 |
| Total Liabilities And Equity | $207,142 | $220,196 | $225,477 | $241,703 | $234,998 |